ES2124533T3 - Anticuerpos monoclonales inmunoestimulantes. - Google Patents

Anticuerpos monoclonales inmunoestimulantes.

Info

Publication number
ES2124533T3
ES2124533T3 ES95910891T ES95910891T ES2124533T3 ES 2124533 T3 ES2124533 T3 ES 2124533T3 ES 95910891 T ES95910891 T ES 95910891T ES 95910891 T ES95910891 T ES 95910891T ES 2124533 T3 ES2124533 T3 ES 2124533T3
Authority
ES
Spain
Prior art keywords
immunostimulant
monoclonal antibodies
tumor
elicts
immuno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95910891T
Other languages
English (en)
Inventor
Britta Hardy
Avraham Novogrodsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mor Research Applications Ltd
Original Assignee
Mor Research Applications Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Applications Ltd filed Critical Mor Research Applications Ltd
Application granted granted Critical
Publication of ES2124533T3 publication Critical patent/ES2124533T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Detergent Compositions (AREA)

Abstract

UN ANTICUERPO MONOCLONAL QUE TIENE EFECTOS DE INMUNOESTIMULACION SE UNE ESPECIFICAMENTE A CELULAS LINFOBLASTOIDES B E INDUCE LA PROLIFERACION Y ACTIVACION DE LINFOCITOS DE SANGRE PERIFERICOS, Y CUANDO SE INYECTA EN ANIMALES PORTADORES DE TUMORES PROVOCA UN EFECTO ANTI-TUMOR.
ES95910891T 1994-01-31 1995-01-30 Anticuerpos monoclonales inmunoestimulantes. Expired - Lifetime ES2124533T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
ES2124533T3 true ES2124533T3 (es) 1999-02-01

Family

ID=11065761

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95910891T Expired - Lifetime ES2124533T3 (es) 1994-01-31 1995-01-30 Anticuerpos monoclonales inmunoestimulantes.

Country Status (20)

Country Link
US (1) US5897862A (es)
EP (1) EP0742795B1 (es)
JP (1) JP3478398B2 (es)
CN (1) CN1052733C (es)
AT (1) ATE171461T1 (es)
AU (1) AU693526B2 (es)
CA (1) CA2182289C (es)
DE (1) DE69504955T2 (es)
DK (1) DK0742795T3 (es)
EE (1) EE03285B1 (es)
ES (1) ES2124533T3 (es)
FI (1) FI963004A (es)
IL (1) IL108501A (es)
LT (1) LT4225B (es)
LV (1) LV11624B (es)
MD (1) MD1374G2 (es)
MX (1) MX9603080A (es)
NO (1) NO317020B1 (es)
RU (1) RU2155190C2 (es)
WO (1) WO1995020605A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
WO2006021955A2 (en) * 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
DK2170959T3 (da) * 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
ES2639857T3 (es) 2008-02-11 2017-10-30 Cure Tech Ltd. Anticuerpos monoclonales para el tratamiento del tumor
MD3972C2 (ro) * 2009-03-11 2010-07-31 Ион МЕРЕУЦЭ Remediu şi metodă de tratament al stărilor precanceroase
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
WO2016040892A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
EP3344656A1 (en) 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
AR106184A1 (es) 2015-09-29 2017-12-20 Celgene Corp Proteínas de unión a pd-1 y sus métodos de uso
AU2016348391A1 (en) 2015-11-03 2018-05-17 Janssen Biotech, Inc. Antibodies specifically binding TIM-3 and their uses
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
EP3515944A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING IMMUNE DISORDERS WITH PD-1 BINDING PROTEINS
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation

Also Published As

Publication number Publication date
DK0742795T3 (da) 1999-06-14
AU693526B2 (en) 1998-07-02
IL108501A (en) 1998-10-30
WO1995020605A1 (en) 1995-08-03
MD1374G2 (ro) 2000-09-30
US5897862A (en) 1999-04-27
FI963004A (fi) 1996-09-27
NO963168L (no) 1996-09-27
EE03285B1 (et) 2000-08-15
NO317020B1 (no) 2004-07-26
EP0742795B1 (en) 1998-09-23
LT4225B (en) 1997-10-27
LV11624B (en) 1997-06-20
JP3478398B2 (ja) 2003-12-15
ATE171461T1 (de) 1998-10-15
CA2182289A1 (en) 1995-08-03
IL108501A0 (en) 1994-05-30
JPH09508390A (ja) 1997-08-26
CN1052733C (zh) 2000-05-24
DE69504955T2 (de) 1999-05-27
DE69504955D1 (de) 1998-10-29
MX9603080A (es) 1998-01-31
EP0742795A1 (en) 1996-11-20
CN1145077A (zh) 1997-03-12
FI963004A0 (fi) 1996-07-29
LV11624A (en) 1996-12-20
CA2182289C (en) 2003-10-21
NO963168D0 (no) 1996-07-29
MD1374F2 (en) 1999-12-31
AU1868695A (en) 1995-08-15
RU2155190C2 (ru) 2000-08-27
LT96115A (en) 1997-05-26

Similar Documents

Publication Publication Date Title
ES2124533T3 (es) Anticuerpos monoclonales inmunoestimulantes.
EP0597829A4 (en) NEW MONOCLONAL ANTIBODY DRESSES AGAINST A NEW ANTIGEN ASSOCIATED WITH HUMAN TUMORS.
DE69221147D1 (de) Nicht glycosylierter Anti-CD3-IgG-Antikörper
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
KR970702882A (ko) 암치료 및 암탐지를 위한 종양세포 생성 단백질의 모노클로날 항체(monoclonal antibody to oncofetal protein for treating and detecting cancer)
DE68914244T2 (de) Monoklonaler Antikörper.
ATE71411T1 (de) Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene.
FI973484A (fi) Menetelmä immuunivasteen stimuloimiseksi
DE3586216T2 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
DE3884646D1 (de) Humanes Karcinom-assoziertes Antigen und an dieses Antigen bindende Antikörper.
SE8800886D0 (sv) Immunoglobulin conjugates
DE3785795D1 (de) Monoklonale anti-menschliche magenkrebs-antikoerper.
DE3580482D1 (de) Monoklonale antikoerper und immunisierung damit.
NO890116L (no) Monoklonale antistoffer.
DE3687542T2 (de) Monoklonaler antikoerper gegen humanes protein c.
DK413389D0 (da) Monoklonale antistoffer
DE68916088T2 (de) Anti-CPBII-monoklonaler Antikörper.
NO903788D0 (no) Monoklonalt antistoff mot protein c.
ATE58173T1 (de) Monoklonale antikoerper und immunisierung damit.
NO914094D0 (no) Nytt monoklonalt antistoff mot nytt antigen forbundet medhumantumorer
DK220688D0 (da) Monoklonalt antistof

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 742795

Country of ref document: ES